Background: This study was designed to assess whether preoperative trigger-site confirmation using botulinum toxin type A injections significantly improved migraine surgery outcomes. Methods: The medical charts of 335 migraine surgery patients were reviewed. Patients who received stepwise diagnostic botulinum toxin type A injections were placed in the botulinum toxin type A group (n ϭ 245). Patients who did not receive botulinum toxin type A or received only therapeutic botulinum toxin type A were placed in the control group (n ϭ 90). The preoperative and 12-month postoperative migraine headache frequency, duration, and intensity were compared to determine the success of the operations. Results: Seventy-two of 90 control patients (80 percent) experienced a significant improvement (a decrease of at least 50 percent in migraine headache frequency, duration, or intensity) at 12 months after surgery, with 29 (32 percent) reporting complete elimination. Of the 245 botulinum toxin type A patients, 207 (84 percent) experienced a significant improvement, with 89 (36 percent) experiencing complete elimination. The surgical success rate of the botulinum toxin type A group was not significantly higher than that of the control group (p ϭ 0.33). Conclusions: Confirmation of trigger sites using botulinum toxin type A does not significantly improve the outcome of migraine surgery. Although botulinum toxin type A can be a useful diagnostic tool, this study demonstrates that there is no statistically significant difference between the injection of botulinum toxin type A and the use of a constellation of symptoms to identify trigger sites. (Plast.
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igraine headaches affect over 35 million Americans, or approximately 17 percent of women and 6 percent of men in the United States. [1] [2] [3] [4] Approximately one-fourth of all households has one member who suffer from migraine headaches. 1 The symptoms commonly interfere with daily function and include unilateral or bilateral throbbing pain, nausea, vomiting, photophobia, and phonophobia. 5 Most migraine headache sufferers manage their symptoms with a combination of nonpharmacologic treatment (e.g., avoiding environmental triggers) and pharmacologic interventions (e.g., acute abortive, acute analgesic, and prophylactic medications). 2, 3 It is estimated that the annual cost for these medications alone is $1.5 billion and the overall cost of treatment of migraine headaches is $13 billion.
at reducing migraine headaches than sham operations, 8 and results have been replicated by other research teams. 9, 10 Migraine surgery can be performed at four common trigger sites: trigger site I, frontal triggers, where glabellar muscles or vessels accompanying the nerves may irritate the supratrochlear and supraorbital nerves to cause frontal headaches; trigger site II, temporal triggers, where the temporalis muscle or the vessels adjacent to the nerve may cause inflammation of the zygomaticotemporal branch of the trigeminal nerve to induce temporal headaches; trigger site III, rhinogenic triggers, where intranasal abnormality (e.g., deviated septum, spurs, contact between the turbinates and the septum, concha bullosa, septa bullosa) may irritate the trigeminal end branches to cause paranasal and retrobulbar headaches; and trigger site IV, occipital triggers, where the semispinalis capitis muscle or the occipital artery can irritate the occipital nerve to cause occipital headaches.
Localized botulinum toxin type A injections have been used to detect and confirm suspected trigger sites I, II, and IV in migraine headache patients before surgery. Botulinum toxin type A is a 1295-amino acid neurotoxin derived from the bacterium Clostridium botulinum, and acts to interrupt neuromuscular transmission by blocking the presynaptic release of acetylcholine. 11 The onset of action of botulinum toxin type A begins after 3 to 4 days, and the neuromuscular junction typically regains its full function 3 to 4 months after initial injection. Injections are targeted directly into muscle, where nerve terminals reside, to weaken the musculature. Aside from diagnostic purposes, botulinum toxin type A injections have also been approved by the U.S. Food and Drug Administration for temporary reduction of migraine headaches. 12 Therapeutic botulinum toxin type A injections are administered in multiple sites per visit in the head and neck to induce maximal effect on migraine headaches. 12 In contrast, preoperative diagnostic botulinum toxin type A injections are administered at one trigger site per visit, starting with the most common and severe trigger site based on the patient's constellation of symptoms. If necessary, subsequent trigger-site injections are given 1 month apart, up to a maximum of three sites, until all trigger sites are confirmed. 13 A potential benefit of testing with botulinum toxin type A is that it may complement and/or confirm suspected trigger sites. The shortcoming of testing with botulinum toxin type A is the lengthy diagnostic period, which may significantly delay surgical intervention. Diagnostic trigger-site injection may take up to 3 months, as only one trigger site is injected per month. In addition, surgery cannot be performed within 3 months of injections into the corrugator site, as these muscles atrophy significantly after injection, making resection extremely difficult. Furthermore, this method of detection of the trigger sites is not convenient for out-of-town or out-of-country patients, who will have to travel several times to the site where the treating team resides.
Over the past 5 years, the senior author has gradually reduced the diagnostic use of botulinum toxin type A in his migraine surgery patients because the majority of his patients were from outside the greater Cleveland, Ohio, area. It is suspected that the analysis of the patient's constellation of symptoms and the physical examination can be as effective at predicting migraine trigger sites as preoperative testing with botulinum toxin type A. The constellations of symptoms for each trigger site are listed in Tables 1 through  4 . The purpose of this study is to evaluate whether preoperative trigger-site detection with botulinum toxin type A significantly increases migraine surgery success.
PATIENTS AND METHODS

Patient Selection
Institutional review board approval was obtained for this retrospective chart review study. The subjects consisted of patients who had undergone migraine surgery performed by a single surgeon (B.G.) between January 1, 2001, and March 31, 2010, had been followed for at least 1 year, and had completed a 12-month follow-up survey. There were 335 patients who fit these in- Plastic and Reconstructive Surgery • February 2012 clusion criteria. All patients completed a baseline Migraine Headache Questionnaire before surgery and at 12 months after surgery. These self-reported questionnaires assess the frequency (migraines per month), duration (in days), and intensity (based on a visual analogue scale from 1 to 10, with 10 being the most severe) of migraine headaches experienced by each patient before and after surgery.
Patients were grouped into either the botulinum toxin type A group or the control group. The patient's medical records indicated whether the patient had received preoperative diagnostic botulinum toxin type A injections performed at suspected trigger sites. Although many migraine patients received multiple head and neck botulinum toxin type A injections for therapeutic purposes, these generalized injections were not site-specific and did not contribute to the localization of trigger sites. Only the patients who received diagnostic, stepwise, single-site botulinum toxin type A injections strictly for trigger-site determination were grouped into the botulinum toxin type A group. The control patients either never received botulinum toxin type A or had received multiplesite botulinum toxin type A injections purely for therapeutic purposes.
Surgical Procedures
Surgery was performed on one or any combination of trigger sites in the same setting: trigger site I (frontal trigger site), removal of the glabellar muscle group (corrugator supercilii, depressor supercilii, and the lateral portion of procerus muscles) to decompress the supraorbital and supratrochlear nerves; trigger site II (temporal trigger site), avulsion of the zygomaticotemporal branch of the trigeminal nerve; trigger site III (rhinogenic trigger site), septoplasty and turbinectomy; and trigger site IV (occipital trigger site), removal of a small segment of the semispinalis capitis muscle to decompress the greater occipital nerve or remove the occipital artery. Surgery was performed in the same way for both the botulinum toxin type A and control groups. A more in-depth description of the above procedures can be found in our previously published reports. [13] [14] [15] [16] [17] [18] [19] [20] 
Statistical Analysis
The migraine headache index was calculated by multiplying the frequency, duration, and intensity of migraine headaches. A 50 percent or greater reduction in migraine headache index at 12 months indicated a successful operation. Twotailed, two-sample homoscedastic t tests were used to compare 12-month success rates of the botulinum toxin type A and control groups. The mean migraine index, frequency, duration, and intensity at 12 months after surgery and baseline were also compared within and between the botulinum toxin type A and control groups. The surgical success at specific trigger sites was also analyzed. A 
RESULTS
Overall Surgery Outcome: Botulinum Toxin Type A versus Control
Of the 335 patients included in this study, 245 received diagnostic stepwise injections of botulinum toxin type A (botulinum toxin type A group) and the remaining 90 patients either never received botulinum toxin type A or previously received nondiagnostic multiple-site botulinum toxin type A injections for therapeutic purposes only (control group). Of the 245 botulinum toxin type A patients, 207 (84 percent) experienced a greater than or equal to 50 percent reduction in migraine index, with 89 (36 percent) experiencing complete elimination of migraine headaches. Of the 90 patients in the control group, 72 (80 percent) experienced a greater than or equal to 50 percent reduction in migraine index, with 29 (32 percent) reporting elimination. The surgery success rates (percentage of patients who experienced Ն50 percent reduction in migraine index) of the botulinum toxin type A group (84 percent) and control group (80 percent) were not significantly different (p ϭ 0.33). The percentage of migraine elimination in the botulinum toxin type A group (36 percent) and the control group (32 percent) were also not significantly different (p ϭ 0.49). The mean reduction in migraine index was 72.9 Ϯ 57.1 percent in the botulinum toxin type A group compared with 68.4 Ϯ 51.2 percent in the control group (p ϭ 0.51).
Surgery Outcome by Migraine Variable
In the control group, all measured variables improved significantly at 12 months (Table 5 ). The mean migraine frequency was 17.3 Ϯ 9.5 at baseline compared with 7.3 Ϯ 9.1 at 12 months (p Ͻ 0.0001). The mean migraine duration was 1.0 Ϯ 1.1 days at baseline compared with 0.6 Ϯ 1.2 days at 12 months (p Ͻ 0.002). The mean migraine intensity at baseline was 8.5 Ϯ 2.3 compared with 4.7 Ϯ 3.6 at 12 months (p Ͻ 0.0001). The mean migraine index at baseline was 91.2 Ϯ 94.5 compared with 7.1 Ϯ 13.2 at 12 months (p Ͻ 0.0001).
In the botulinum toxin type A group, all measured variables also improved significantly at 12 months ( Table 5 ). The mean migraine frequency was 11.7 Ϯ 8. At baseline, the mean migraine frequency was significantly higher in the control group than in the botulinum toxin type A group (p Ͻ 0.0001). The mean baseline migraine intensity was also significantly higher in the control group than in the botulinum toxin type A group (p Ͻ 0.001). There was no significant difference between the mean migraine duration in the control and botulinum toxin type A groups at baseline (p ϭ 0.73).
Surgery Outcome by Trigger Site: Botulinum Toxin Type A versus Control
The success rates for all operations that included trigger site I were not significantly different in the botulinum toxin type A (87 percent) and control (90 percent) groups (p ϭ 0.53). The success rates for all operations that included trigger site II were also not significantly different between groups (p ϭ 0.50). Finally, the success rates for trigger site IV operations were not statistically different between botulinum toxin type A (90 percent) and control (81 percent) groups (p ϭ 0.14). These results are summarized in Table 6 .
Surgery Outcome by Year
The practice of using botulinum toxin type A testing as a diagnostic tool for trigger-site confirmation decreased steadily each year starting in 2006 (Table 7) 
DISCUSSION
An increase in the number of patients traveling long distances along with development of the constellation of the symptoms that were associated with specific trigger sites compelled the senior author to rely on the symptoms along with computed tomographic scan findings (only for the rhinogenic migraine headaches) in detecting the trigger sites. The absence of a statistical difference between surgical success rates in botulinum toxin type A and control groups in this study suggests that testing with botulinum toxin type A is not always necessary for the localization of migraine trigger sites. Although both groups had success rates greater than 80 percent, there was still a small contingent of patients whose symptoms were not significantly alleviated by surgery. It is the senior author's belief that the failure to detect and deactivate the trigger sites contributed substantially to this suboptimal success rate. One has to consider that in our previous studies, approximately 10 percent of the patients were excluded based on the lack of response to the injection of botulinum toxin type A. It is difficult to ascertain whether this contributed to a slight but statistically nonsignificant reduction in the success rate. Furthermore, 11 percent of patients who underwent surgery at all four trigger sites did not respond positively, suggesting the presence of additional trigger sites. Less common trigger sites have been discovered over the past 11 years, including the auriculotemporal branch of the trigeminal nerve and the lesser 2001  21  17  81  86  78  14  100  2002  90  80  89  97  89  3  100  2003  46  40  87  72  88  28  85  2004  40  34  85  82  82  18  100  2005  42  36  86  83  83  17  100  2006  18  12  67  72  62  28  80  2007  16  12  75  56  100  44  43  2008  17  16  94  47  100  53  89  2009  33  25  76  21  71  79  77  2010  12  8  67  17  100  83  60 BTA, botulinum toxin type A.
Volume 129, Number 2 • Trigger Sites and Migraine Headaches occipital nerves. The surgical intervention for these additional trigger sites has been discussed in previous publications. 7, 21 The data also indicate that the mean baseline frequency and severity of migraine headaches experienced by patients in the control group were higher than in the botulinum toxin type A group. This trend correlates with the increase in the complexity of cases in recent years. As knowledge of the pathophysiology of migraine headaches and of anatomical variations has grown, so has the complexity of patient cases-patients who would have been rejected for surgery several years ago are now accepted. Many of these complex control cases included patients who were unresponsive to botulinum toxin type A injections. Despite the higher baseline migraine frequency and intensity in control patients, they experienced essentially the same average reduction in migraine index as the botulinum toxin type A patients, indicating that a higher baseline migraine index does not hinder the success of the operations.
Testing with botulinum toxin type A has been a part of the diagnostic protocol for migraine surgery since 2000, when the senior author first used surgical techniques for migraine management. However, stepwise testing with botulinum toxin type A requires multiple visits at 1-month intervals and is not feasible for out-of-state or out-of-country patients, who must travel long distances for singlesite botulinum toxin type A injections in multiple, consecutive months. Furthermore, botulinum toxin type A may also be ineffective in some individuals who develop blocking antibodies to the toxin, leading to false-negative results for triggersite identification. [22] [23] [24] Although the prevalence of botulinum toxin type A resistance is less than 5 percent, 25 testing with botulinum toxin type A in these patients may actually hinder the correct diagnosis of trigger sites. In addition, botulinum toxin type A injection adds to the cost of migraine care that may not be reimbursed by a third party.
If the patient's constellation of symptoms does not clearly indicate a specific trigger site, singlesite phased injection of botulinum toxin type A or a nerve block can abet the confirmation. Unlike botulinum toxin type A, local anesthetics such as lidocaine have a fast onset of less than 90 seconds and a short half-life of less than 2 hours, 26 allowing almost immediate relief from migraine headache symptoms if injected into the correct trigger site(s). However, a nerve block is only helpful when applied in patients who present with migraine headaches at the time of the office visit.
We believe the trigger site can be reliably identified by analyzing each patient's symptoms, physical examination, and computed tomographic scan without the necessary use of preoperative botulinum toxin type A injections. The most reliable of these symptoms is the precise location of the pain at the beginning of migraine headaches. However, botulinum toxin type A injection was extremely helpful in the development of Tables 1 through 4 . Thus, we recommend injection of botulinum toxin type A or nerve blocks to confirm the trigger sites for those surgeons who are in their early stages of serving these patients, until they develop the necessary level of comfort and expertise.
CONCLUSIONS
This study confirms that the use of stepwise botulinum toxin type A injections at potential trigger sites before migraine surgery does not significantly improve surgical outcome. Trigger sites can be successfully determined using the patient's constellation of symptoms alone.
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